ArticleiScience2026
Thermoregulated photothermal therapy for bone defects using graphene oxide hydrogel with mesoporous silica-derived phase-change nanocapsules.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical translation of photothermal therapy for bone repair is hindered by the risk of thermal damage to surrounding healthy tissues due to uncontrolled high temperatures. We addressed this by integrating phase change materials (PCMs) into a photothermal platform, developing a hydrogel scaffold with temperature regulation. Polyethylene glycol (PEG) was encapsulated in mesoporous nanosilica (MSNs) to form nanocapsules, achieving 82.5% efficiency. This encapsulation prevents PEG leakage and enhances thermal regulation and bioactivity. Graphene oxide (GO) was integrated into an alginate-chitosan matrix, yielding a GO/chitosan scaffold containing PEG@MSNs nanocapsules. The scaffold exhibits a phase transition at 41.2°C and latent heat of 95.5 J/g. Characterization confirms its physicochemical properties, biocompatibility, and cell affinity meet bone repair requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.